Company intelligence / Profile preview

Beijing Boquan Jian Pharmaceutical Technology

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Beijing Boquan Jian Pharmaceutical Technology is a Chinese biotechnology company focused on the research and development of innovative small molecule drugs, particularly in the fields of metabolic and endocrine diseases. The company is notably involved in the development of next-generation treatments for Type 2 diabetes and hyperuricemia. Their pipeline includes BQJ-101, a novel SGLT2 inhibitor, and other candidates targeting metabolic pathways. Boquan Jian operates primarily out of Beijing, leveraging local R&D expertise to advance its clinical programs through the Chinese regulatory landscape.

Therapeutic areas: EndocrinologyRheumatologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Beijing Boquan Jian Pharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Boquan Jian Pharmaceutical Technology.

Explore the full profile